Atypical oral candidiasis in a psoriatic patient during targeted immunotherapy with an interleukin 17 inhibitor (secukinumab)

Concurrent chronic hyperplastic candidosis and oral lichenoid lesion as adverse events of secukinumab therapy

(2021) CS Farah   AUSTRALIAN DENTAL JOURNAL

Characterization of oral candidiasis and the Candida species profile in patients with oral mucosal diseases

(2019) Lijun Hu et al.   MICROBIAL PATHOGENESIS

Effect of Probiotics on Oral Candidiasis: A Systematic Review and Meta-Analysis

(2019) Tiziana Mundula et al.   Nutrients

Evaluation of an innovative oral brush for potential applications using liquid based cytology

(2018) Omar Kujan et al.   Journal of Oral Science

Candida infections in psoriatic patients on anti-IL17 therapy: a case series

(2018) Manuela Papini et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study

(2016) K. Yamasaki et al.   BRITISH JOURNAL OF DERMATOLOGY

New therapies for psoriasis and psoriatic arthritis

(2016) Christopher T. Ritchlin et al.   CURRENT OPINION IN RHEUMATOLOGY

Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study

(2016) Hidemi Nakagawa et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Oral lichen planus associated with candidiasis during secukinumab treatment

(2016) Takaya Komori et al.   JOURNAL OF DERMATOLOGY

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

(2016) Kenneth B. Gordon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE)

(2015) D. Thaçi et al.   BRITISH JOURNAL OF DERMATOLOGY

IL-17–Mediated Immunity to the Opportunistic Fungal PathogenCandida albicans

(2015) Heather R. Conti et al.   JOURNAL OF IMMUNOLOGY

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2015) Iain B McInnes et al.   LANCET

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

(2015) Philip J. Mease et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral lichen planus: An update on etiology, pathogenesis, clinical presentation, diagnosis and management

(2015) Sonia Gupta et al.   INDIAN JOURNAL OF DERMATOLOGY

Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)

(2014) A. Blauvelt et al.   BRITISH JOURNAL OF DERMATOLOGY

Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment

(2014) Kim Papp et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

(2014) Richard G. Langley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral candidiasis in patients with psoriasis: Correlation of oral examination and cytopathological evaluation with psoriasis disease severity and treatment

(2013) Bruna Lavinas Sayed Picciani et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Immunity to infection in IL-17-deficient mice and humans

(2012) Sophie Cypowyj et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis

(2009) Heather R. Conti et al.   JOURNAL OF EXPERIMENTAL MEDICINE